Skip to main content
Monthly Archives

June 2015

chimes society

NeuroAiD™ has shown persistent long-term benefits after an initial 3-month treatment following stroke onset

By News

Moleac is pleased to announce the release of the CHIMES-E study results published online in the journal Cerebrovascular Diseases1 . It provides convincing data on NeuroAiD which confirm its persistent long-term benefits on patients’ recovery after an ischemic stroke. The CHIMES-E study results were first announced by Prof. Christopher Chen (CHIMES-E co-principal investigator) during the European Stroke Organization Conference (ESOC 2015) in Glasgow, April 17- 19, as part of the Scientific Program during the Clinical Trial session.

The CHIMES-E study is a planned, international and multicenter study performed in a blinded and placebo-controlled manner. It has included 880 patients from the CHIMES study who have suffered an ischemic stroke of intermediate severity within 72 hours, treated with NeuroAiD™ or placebo for 3 months after the initial stroke. The main purpose of this study was to evaluate the effects of an initial 3-month course with NeuroAiD™ on long-term outcomes for up to 2 years.

This study has showed that NeuroAiD™ increases significantly the odds of achieving functional independence at 6 months which persisted up to 18 months after stroke, as measured by the mRS. All these results were consistent at various time points and seen on 2 indices, i.e. mRS and BI. It also provided further long-term safety data on NeuroAiD™, even when combined with other stroke treatments. “These persistent benefits seen up to 18 months are a clinical confirmation of the previously established neurorestorative properties (i.e. neuroplasticity and neurogenesis) of NeuroAiD™, and suggest that it may be beneficial to extend NeuroAiD™ treatment beyond the first 3 months after stroke,” said Prof. Christopher Chen, neurologist at the National University of Singapore and the principal investigator of the CHIMES study. “The CHIMES-E study provides new insight on the need for long-term assessment of post-stroke recovery in clinical trials of agents with neuroprotective and neurestorative properties such as NeuroAiD.

These results confirm the hypothesis raised by the CHIMES investigators: longer treatment duration and follow-up beyond 3 months of stroke patients is needed to assess stroke recovery2

About CHIMES Society

The CHIMES Society is an international academic industry collaboration with the objective to establish new stroke treatments. It is a Singaporean non-profit society founded by a group of experts in stroke and South-East Asian stroke clinicians interested to implement a research project: the NeuroAiD™ Efficacy on stroke recovery trial (CHIMES trial).

The CHIMES-E Study was supported by the CHIMES society and grants were received by CHLC from the National Medical Research Council in Singapore (NMRC) which supports the implementation of CHIMES trial in Singapore.

About Moleac

To address therapeutic gaps, Moleac has pioneered a new drug development approach, looking at sources of innovation from Natural Medicines, hence shortening considerably drug development cycle time and investment to bring medicine to sufferers’ unaddressed needs. Moleac’s neurorestorative compound NeuroAiD™ reaches patients in more than 30 countries.

For more information,


1- Venketasubramanian N, et al. CHInese Medicine NeuroAiD Efficacy on Stroke Recovery – Extension Study (CHIMES-E): A Multicenter Study of Long-Term Efficacy. Cerebrovascular Diseases 2015;44 39:309–318.

2- Venketasubramanian N, et al. Chinese medicine NeuroAiD efficacy stroke recovery-extension study (CHIMES-E study): an observational multicenter study to investigate the longer-term efficacy of NeuroAiD in stroke recovery. Cerebrovasc Dis 2013; 35(suppl 1):18–22.

Archived News

By News

Press Releases


June 2015 Media article “Chinese Herbal Medicine May Have Delayed Benefit in Stroke”

A press article detailing the exciting new clinical results of CHIMES-E study showing the persisting benefits of NeuroAiD in post-stroke recovery was published online on

June 2015 Press Release “NeuroAiD™ has shown persistent long-term benefits after an initial 3-month treatment following stroke onset”

Moleac is pleased to announce the release of the CHIMES-E study results published online in the journal Cerebrovascular Diseases. It provides convincing data on NeuroAiD which confirm its persistent long-term benefits on patients recovery after an ischemic stroke. The CHIMES-E study results were first announced by Prof. Christopher Chen (CHIMES-E co-principal investigator) during the European Stroke Organization Conference (ESOC 2015) in Glasgow, April 1719, as part of the Scientific Program during the Clinical Trial session.



August 2014 Presentation 27th August 2014 – Moleac’s CEO, David Picard, presented on “E-Commerce: Going beyond the traditional visibility of Pharma Products” at the Pharmaceutical Congress Asia that was held from 26th to 29th August 2014 at the Park Royal Hotel in Singapore. His presentation included an introduction to NeuroAiD™ as well as Moleac’s Corporate Social Responsibility (CSR) activities and commitment to patient care via the Stroke Recovery Coach. EN
July 2014 Press Article “TCM trial for stroke survivors – Professor Christopher Chen is interviewed about the NeuroAiD™II in Vascular Cognitive Impairment Study (NEURITES) in The Straits Times.” EN      
July 2014 Press Article “NUS studies the efficacy of traditional Chinese Medicine in treating stroke’s after-effects – featured in Lian He Zao Pao” CH      
April 2014 Press Release Moleac is happy to announce the appointment of Elmar Schnee as non-executive Chairman of the company EN      
Jan – Feb 2014 Press Article “Demonstrated efficiency of NeuroAiD™”

A press article detailing the exciting latest clinical data on vascular events reduction after a stroke has been published in the magazine “Actifs”

EN / FR      


Oct 2013 Press Release NeuroAiD™, a treatment for post-stroke recovery, reduced early cardiovascular events and deaths by half after stroke

Singapore, 21st October 2013 – Early vascular events are an important cause of morbidity and mortality in the first three months after a stroke. The CHIMES Study is a placebo-controlled trial of NeuroAiD™, having included 1099 patients with ischemic stroke and receiving appropriate secondary prevention treatments. The frequency of early cardiovascular events and deaths during the 3-month follow-up was significantly halved in the NeuroAiD™, group (p=0.025) without an increase in bleeding rate and non-vascular deaths.

Jul 2013 Radio Interview Presenter of ‘Body & Soul’ program on 938LIVE Daniel Martin interviews Prof Christopher Chen on Stroke in Singapore and the CHIMES Study.

938LIVE is a poplar news-focused radio station. ‘Body & Soul’, since it first aired in 2007, has been Singapore’s only dedicated daily health radio talk-show.

Jun 2013 Press Release Stroke Treatment based on Traditional Chinese Medicine increases chances of recovery

  • CHIMES Society, a unique international partnership of experts in strokes undertakes first large-scale endeavour to investigate the use of a treatment derived from natural substances in stroke management.
  • Rigorous study shows ischemic stroke patients of intermediate severity who take NeuroAiD at acute stage had an 11 % increase in the odds of achieving independence and being able to perform daily activities at the end of three months.
  • Effect was even greater when NeuroAiD was started beyond 48 hours after stroke onset, with an increase of 39%.
Mar 2013 Press Release NeuroAiD™, a stroke treatment based on traditional Chinese medicine, more than doubles the chances of achieving independence after stroke

Singapore, March 19 2013: Authors of a medical paper published in this month’s Cerebrovascular Diseases journal found that NeuroAiD™ significantly improves patients’ independence after suffering a stroke compared to other control groups. During the studies stroke patients taking NeuroAiD™ were twice as likely able to take care of themselves and speak freely. The study also showed that NeuroAiD™ improved patients’ chances of performing daily activities after stroke.

Jan 2013 Media Coverage NurAiD™II is featured on France 24 with an interview with neurologist and prescriber Dr Charles Siow, CEO David Picard and lead investigator of the CHIMES trial Prof Christopher Chen about bringing Chinese medicine into the Western standards to fill the gap of improving recovery after stroke. EN      


Jul 2011 Press Release Moleac Announces the Beneficial Effect of NeuroAiD (TM) (MLC 901) in Protecting the Brain Against Global Ischemia

“Neuropharmacology” published a paper establishing NeuroAiD’s reparativeeffects on global cerebral ischemia.

Feb 2011 Press Release Prof. Michel Lazdunski receives Gold Medal from the Jung Foundation for his work on ion channels.

We are happy to announce that Prof. Michel Lazdunski, vice president research of Moleac, has been awarded one of the most prestigious international awards – the 2011 Gold Medal of the Jung Foundation for Science and Research, for his work on ion channels.



Mar 2010 Press Release Moleac Receives BioSpectrum Asia Emerging Company of the Year 2010 Award

Moleac Pte Ltd has been granted the Emerging Company of the Year 2010 Award, by Biospectrum, the leading integrated media platform for the Life Science Industry in Asia Pacific.

Feb 2010 Press Release Breakthrough Results on Neuroprotective and Neurogenerative Properties of NeuroAiD

The January issue of “Neuropharmacology”, publishes the article entitled “Neuroprotective and Neuroproliferative Activities of NeuroAiD”, reporting pharmacological data establishing NeuroAiD (MLC 601) protective effects on neuronal and brain injuries as well as its effectiveness in neurological functions recovery.



Sep 2009 The Business Times Faster, cheaper way to developing drugs (next paragraph) Moleac’s hybrid approach has been used to successfully develop and market its stroke recovery drug in 3 years, for less than US$10m EN      
Apr 2009 Press Release Moleac named Singapore Entrepreneurial Company of the year at the Frost & Sullivan Excellence in Healthcare Award

An important confirmation of Moleacs outstanding performance in 2008.

Apr 2009 The Business Time Moleac is rewarded for its stroke treatment drug NeuroAiD EN      
Apr 2009 Medical Tribune TCM agent shows promise in post-stroke recovery, says study
An article on clinical trials performed in China shows promising results and paves the first steps towards making NeuroAiD an evidence-based medicine.
Feb 2009 Press Release Moleac Prof. Michel Lazdunski appointed as Vice-President Research of Moleac Pte. Ltd.

A world-renown scientific leader is now in charge of the study on NeuroAiD mechanism of action.

Feb 2009 Medical Tribune Evidence-based TCM makes headway
NeuroAiD™ is one of the first TCM medications to be put under the microscope of rigidly-controlled clinical trials CHIMES continues to make noises in Singapore and giving hope to stroke patients.


Dec 2008 BioSpectrum Ancient medicines, source of Pharma innovation – Moleac aims to bring the science behind traditional medicines to the next level and establishes their quality and safety through accepted modern evaluation practices. EN      
Oct 2008 Le Quotidien du Medecin (original in French) Un composé issu de la médecine chinoise au banc d’essai. L’un des magazines les plus renommés parmi les médecins français a accordé une attention particulière à NeuroAiD™.

A mixture derived from Chinese medicine on trial. One of the most prestigious magazine for doctors in France has paid special attention to NeuroAid&trade.

May 2008 The Edge Bridging the gap between East and West – Moleac unique business model differs itself from other biotech companies in valuations or the way in which the investors consider. EN      
Apr 2008 The Business
Times Weekend News
China Stroke Drug Holds Promise. EN      
Apr 2008 The Business
Times Weekend News
Three-Minute Digest: US$3.5M
more for Moleac for stroke drug


Sep 2007 The Business
Times Weekend
Largest TCM trial outside China. EN      
Sep 2007 Singapore Straits Times TCM drug for stroke to undergo clinical trials. EN      
Sep 2007 Channel News Asia Channel News Asia 880 stroke patients in Singapore to undergo TCM clinical trial. EN wmv
Sep 2007 The Business Times The Business Times Moleac plans to test traditional Chinese stroke drug. EN      
Sep 2007 Moleac announces CHIMES Largest ever clinical trial on stroke recovery medication to be initiated in Singapore and Philippines. EN      
Sep 2007 Reuters Singapore firm tests traditional Chinese stroke drug. EN      
May 2007 Medical News Today Going West with Eastern Medicine. EN      
Apr 2007 AsiaOne Chinese medicine to help stroke victims EN      
Apr 2007 Straits Times Rise of Traditional Chinese Medicine EN      


Dec 2006 Reuters Moleac Turns TCM into Stroke Treatment EN      
Dec 2006 Focus Autumn Moleac: Therapeutics from East to West. EN      
Dec 2006 Today’s Manager Uncovering New Drugs from Traditional Cures. EN      
Oct 2006 The Business Times New TCM drug offers hope for stroke patients. EN      
Sep 2006 Press release Moleac and China healthcare tie up to offer a more comprehensive rehabilitation treatment for stroke patients. EN      
Aug 2006 The Edge Traditional Therapy EN      
Aug 2006 Talking Science (children magazine) East meets West EN      
Aug 2006 EZHealth NeuroAiD for stroke patients EN      
Jun 2006 Press release NeuroAiD offers new hope to patients EN      
Apr 2006 Singapore Business Visitor The Next Wave EN      
Jan 2006 Asia Pacific Biotech Journal Moleac: Flowing Therapeutics from the East to the West and Expertise from the West to the East. EN